We are testing a combination of azacitidine, venetoclax, and tagraxofusp for patients with higher-risk chronic myelomonocytic leukemia. The study aims to evaluate how well this treatment works and its safety.
Health conditions and diseases that the clinical trial is designed to study and treat.
Chronic Myelomonocytic Leukemia (CMML) is a type of cancer that affects the blood and bone marrow, characterized by the overproduction of monocytes, a type of white blood cell. Symptoms may include fatigue, fever, weight loss, and frequent infections.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
